Pathophysiology of NASH: perspectives for a targeted treatment.
about
Non-alcoholic fatty liver disease: what the clinician needs to know.Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosisTh17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitisMolecular Pathogenesis of NASHHepatic fat fraction and visceral adipose tissue fatty acid composition in mice: Quantification with 7.0T MRI.Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments.Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis.Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children.Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice.Induction of heme oxygenase-1 with dietary quercetin reduces obesity-induced hepatic inflammation through macrophage phenotype switching.Chronic Exposure to Low Doses of Dioxin Promotes Liver Fibrosis Development in the C57BL/6J Diet-Induced Obesity Mouse Model.Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.Autophagy in chronic liver diseases: the two faces of Janus.Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis.Hepatocellular carcinoma is accelerated by NASH involving M2 macrophage polarization mediated by hif-1αinduced IL-10Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006.Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis.Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.Effect of methionine-deficient and methionine-supplemented diets on the hepatic one-carbon and lipid metabolism in mice.Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.[Autophagy in chronic liver diseases: a friend rather than a foe?]Long-term dietary supplementation with low-dose nobiletin ameliorates hepatic steatosis, insulin resistance, and inflammation without altering fat mass in diet-induced obesity.Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver.Lipoic Acid Prevents High-Fat Diet-Induced Hepatic Steatosis in Goto Kakizaki Rats by Reducing Oxidative Stress Through Nrf2 Activation
P2860
Q24563068-00C6D6D8-B051-4305-951F-50C98DBF593DQ26829503-9C73E88F-87CD-45DB-85D0-C71C5A2A5E1AQ27021577-96E0D874-A166-4B78-8FCB-15B4FA86F66FQ28067738-6A7C17FF-7D8D-4631-AE1D-B62260E0E5F6Q28071265-AF551F56-615D-4F44-AE45-3C0B15E15425Q30488507-55FD17A1-7BE1-4681-8765-92DF8A8E214EQ34406806-2768DAF8-E1E9-4C5C-BBDC-E4F093E71B33Q34458652-7F596720-D997-46B3-923E-D69B21307ABAQ36246407-2E2D66DB-5FA0-4FE0-BF27-9A9E72254CC2Q36900196-510F5019-BE74-4131-B8D4-52B443E45602Q37193179-64698098-F7CD-4F7F-810E-FCCBB7BBCEF1Q37448506-2393015F-ADD8-4C92-A87F-DBA06D9C0B95Q37674933-BD313A74-D3D5-4C12-A689-9A2F4E1E840DQ38160948-BA64596A-D58B-405B-A388-5E8693405A0EQ38599131-7F771AC1-55CC-4362-8C3F-D1E536FE3162Q39024897-A58B8183-29CB-478E-B82E-7542A9730F0EQ39109576-065D812E-9158-4B5D-AAFD-633467A80FDEQ39181831-958A0E98-13EA-46F6-9D72-C5225B8E3C12Q39976307-BC132749-D2DA-4C44-BED2-7C4970E1FC18Q41487407-56CED78B-4A83-4AF4-946B-D30B01E5AA20Q46554515-B6722E9A-8A32-4164-9855-C097562A9C6DQ51069151-7067D590-8D63-4214-8AA8-82F66BE50464Q51140230-0AC5404D-7BC2-4C5D-8FCD-3ABCD8DCAD6AQ52725161-61E42DF0-C577-4387-AAC6-26A27D1FE089Q52884774-794C3CB4-1C4E-408F-9F7C-57D3F58AF9C7Q53752953-18BFBDF2-6D6F-446E-BEA4-A54FDDE765DAQ54969856-16A1EF4E-E3FF-48BC-81A1-F52C1FCCD620Q58749606-B30D232A-8EF9-4092-A436-E2B3ECD85F13
P2860
Pathophysiology of NASH: perspectives for a targeted treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pathophysiology of NASH: perspectives for a targeted treatment.
@en
Pathophysiology of NASH: perspectives for a targeted treatment.
@nl
type
label
Pathophysiology of NASH: perspectives for a targeted treatment.
@en
Pathophysiology of NASH: perspectives for a targeted treatment.
@nl
prefLabel
Pathophysiology of NASH: perspectives for a targeted treatment.
@en
Pathophysiology of NASH: perspectives for a targeted treatment.
@nl
P2860
P50
P1476
Pathophysiology of NASH: perspectives for a targeted treatment.
@en
P2860
P304
P356
10.2174/13816128113199990344
P577
2013-01-01T00:00:00Z